- Home
- KRO vs MYGN Comparison
KRO vs MYGN Comparison
Compare KRO & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRO
- MYGN
- Stock Information
- Founded
- KRO 1916
- MYGN 1991
- Country
- KRO United States
- MYGN United States
- Employees
- KRO N/A
- MYGN N/A
- Industry
- KRO Major Chemicals
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- KRO Industrials
- MYGN Health Care
- Exchange
- KRO Nasdaq
- MYGN Nasdaq
- Market Cap
- KRO 803.0M
- MYGN 744.7M
- IPO Year
- KRO N/A
- MYGN 1995
- Fundamental
- Price
- KRO $6.48
- MYGN $5.34
- Analyst Decision
- KRO Strong Sell
- MYGN Hold
- Analyst Count
- KRO 2
- MYGN 15
- Target Price
- KRO $7.75
- MYGN $15.14
- AVG Volume (30 Days)
- KRO 236.2K
- MYGN 1.3M
- Earning Date
- KRO 08-06-2025
- MYGN 08-05-2025
- Dividend Yield
- KRO 3.03%
- MYGN N/A
- EPS Growth
- KRO N/A
- MYGN N/A
- EPS
- KRO 0.84
- MYGN N/A
- Revenue
- KRO $1,898,100,000.00
- MYGN $831,300,000.00
- Revenue This Year
- KRO $8.42
- MYGN N/A
- Revenue Next Year
- KRO $11.49
- MYGN $6.68
- P/E Ratio
- KRO $7.90
- MYGN N/A
- Revenue Growth
- KRO 10.42
- MYGN 7.38
- 52 Week Low
- KRO $5.86
- MYGN $3.81
- 52 Week High
- KRO $13.77
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- KRO 49.74
- MYGN 50.85
- Support Level
- KRO $6.32
- MYGN $4.90
- Resistance Level
- KRO $6.79
- MYGN $5.83
- Average True Range (ATR)
- KRO 0.23
- MYGN 0.28
- MACD
- KRO 0.06
- MYGN 0.04
- Stochastic Oscillator
- KRO 66.67
- MYGN 54.21
About KRO Kronos Worldwide Inc
Kronos Worldwide Inc manufactures and sells titanium dioxide pigments. Titanium dioxide is a white inorganic pigment used in various products. The majority of Kronos' sales come from titanium dioxide used for coatings on automobiles, aircraft, machines, appliances, traffic paint, and in both commercial and residential interiors and exteriors. The second product category is titanium dioxide used for plastics such as packaging materials and food packaging, houseware, appliances, toys, and computer cases. The majority of revenue comes from the United States.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.